Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients

Camurus AB's POSITANO study of CAM2029 in patients with polycystic liver disease (PLD) met its primary endpoint, demonstrating a statistically significant 4.3% reduction in height-adjusted liver volume and an 8.7% reduction in total liver cyst volume compared to placebo at week 53 (p=0.044 and p=0.016, respectively). CAM2029 also showed improvements in disease symptoms and was well-tolerated, with a safety profile consistent with other somatostatin receptor ligands; a follow-up Phase 3 study will be discussed with regulatory authorities, offering potential for the first approved treatment for this rare genetic disorder affecting approximately 37,000 people in the US and EU.

Analysis

Camurus AB has reported positive topline results from its POSITANO Phase 2/3 study evaluating CAM2029 in polycystic liver disease (PLD), a rare genetic condition affecting approximately 37,000 individuals in the US and EU with no currently approved pharmacological treatments. The study successfully met its primary endpoint, with CAM2029 demonstrating a statistically significant relative reduction in height-adjusted liver volume (htTLV) of 4.3% (p=0.044) and a notable 8.7% relative reduction in total liver cyst volume (p=0.016) compared to placebo at 53 weeks. Furthermore, treatment with CAM2029 led to improvements in disease symptoms and patient-reported outcomes, and exhibited a favorable safety profile consistent with established somatostatin receptor ligands, with no new or unexpected safety findings. These encouraging results, combined with CAM2029's Orphan Drug Designation in both the US and EU, strongly position the drug as a potential first-in-class therapy for PLD. Camurus intends to discuss a follow-up Phase 3 study with regulatory authorities, a crucial step towards potential marketing authorization, while long-term efficacy and safety data continue to be collected in a 2.5-year open-label extension study.

Key Decisions for Investors

• Investors should closely monitor Camurus' forthcoming interactions with regulatory agencies regarding the advancement of CAM2029 into a confirmatory Phase 3 trial, as this will be a pivotal de-risking milestone.
• The positive efficacy and safety data for CAM2029 in PLD, an orphan disease with a significant unmet medical need, warrants careful assessment of its commercial outlook and potential impact on Camurus' valuation, especially considering its Orphan Drug Designation.
• Prudent investors should await the full publication of the POSITANO study results and further regulatory feedback before making substantial portfolio adjustments, while recognizing the current data significantly enhances the asset's profile within Camurus' pipeline.